Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 5 versus DEPO TESTOSTERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 5 versus DEPO TESTOSTERONE.
ANDROID 5 vs DEPO-TESTOSTERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Testosterone binds to androgen receptors, activating gene transcription that promotes development of male secondary sexual characteristics, anabolic effects, and erythropoiesis.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
50-400 mg IM every 2-4 weeks
None Documented
None Documented
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
The terminal elimination half-life of testosterone cypionate after intramuscular injection is approximately 8 days, allowing for dosing every 2-4 weeks.
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (90%) and in feces via bile (10%).
Category C
Category D/X
Androgen
Androgen